Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response.
Lemonde
Sylvie
S
Ottawa Health Research Institute (Neuroscience), University of Ottawa, Department of Medicine, Ottawa, Canada, K1H 8M5.
Du
Lisheng
L
Bakish
David
D
Hrdina
Pavel
P
Albert
Paul R
PR
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000483:Alleles; D000928:Antidepressive Agents / Q000627:therapeutic use*; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use; D015331:Cohort Studies; D003866:Depressive Disorder / Q000188:drug therapy* / Q000235:genetics* / Q000523:psychology; D004359:Drug Therapy, Combination; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010869:Pindolol / Q000627:therapeutic use; D010879:Piperazines; D011110:Polymorphism, Genetic / Q000235:genetics*; D011401:Promoter Regions, Genetic / Q000235:genetics*; D011569:Psychiatric Status Rating Scales; D044282:Receptor, Serotonin, 5-HT1A / Q000235:genetics*; D014230:Triazoles / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000928:Antidepressive Agents; D018687:Antidepressive Agents, Second-Generation; D001562:Benzimidazoles; D010879:Piperazines; D014230:Triazoles; D005473:Fluoxetine; D044282:Receptor, Serotonin, 5-HT1A; C098107:flibanserin; C051752:nefazodone; D010869:Pindolol